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The myelodysplastic syndromes (MDS) comprise a haemato-
logically and biologically diverse group of stem cell disorders
characterized by accelerated apoptosis and ineffective haemat-
opoiesis that lead to functional haematopoietic failure (Faderl
& Kantarjian, 2004; Catenacci & Schiller, 2005; Hofmann &
Koefﬂer, 2005; Kurtin, 2006). Classiﬁcation systems for
distinguishing MDS subtypes associated with speciﬁc prog-
nostic signiﬁcance have been developed and include the
French–American–British (FAB) system, the International
Prognostic Scoring System (IPSS) and the World Health
Organization (WHO) classiﬁcation system (Bennett et al,
1982; Greenberg et al, 1997; Vardiman et al, 2002). These
classiﬁcation systems are used clinically in MDS patients to
predict both survival and the risk of evolving to acute myeloid
leukaemia (AML).
Refractory anaemia (RA) resulting from ineffective eryth-
ropoiesis is a major cause of morbidity and mortality in
patients with low-risk MDS (Bowen & Hellstrom-Lindberg,
2001; Hellstrom-Lindberg et al, 2003; Hofmann & Koefﬂer,
2005; Kurtin, 2006). Inﬂammatory cytokines, including
tumour necrosis factor-alfa, transforming growth factor-beta
and interleukin-1 beta have been implicated in the accelerated
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Summary
Patients with myelodysplastic syndromes (MDS) often develop anaemia
resulting in frequent transfusions and fatigue. Darbepoetin alfa is an
erythropoiesis-stimulating agent (ESA) approved for treating chemotherapy-
induced anaemia. This single-arm, phase 2 study examined the efﬁcacy of
darbepoetin alfa 500 lg every 3 weeks (Q3W) for treating anaemia in low-
risk MDS patients (after 6 weeks, poor responders received darbepoetin alfa
500 lg every 2 weeks). The primary end-point was the incidence of erythroid
responses (International Working Group criteria) after 13 weeks of therapy.
Secondary end-points included the incidence of erythroid responses at weeks
28 and 55, [or weeks 27 and 53 for dose escalations to every two weeks
(Q2W)], and safety parameters. Analyses were stratiﬁed by the patient’s
previous ESA therapy status [ESA-naı ¨ve (n = 144) vs. prior ESA-treated
(n = 62)]. After 13 weeks of therapy, 49% of ESA-naı ¨ve patients and 26% of
prior ESA-treated patients achieved a major erythroid response. After
53/55 weeks, 59% of ESA-naı ¨ve patients and 34% of prior ESA-treated
patients achieved a major erythroid response; 82% of ESA-naı ¨ve patients and
55% of prior ESA-treated patients achieved target haemoglobin of 110 g/l.
Thromboembolic or related adverse events occurred in 2% of patients; no
pulmonary embolisms were reported. In conclusion, darbepoetin alfa, 500 lg
Q3W appeared well tolerated and increased haemoglobin levels in low-risk
MDS patients.
Keywords: myelodysplastic syndromes, erythropoiesis-stimulating agent,
erythroid response, haemoglobin, transfusion.
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lineage-speciﬁc cytopenias (including anaemia) associated
with MDS (Raza et al, 1996; Allampallam et al, 2002; Faderl
& Kantarjian, 2004; Stifter et al, 2005; Verma & List, 2005;
Sekeres & List, 2006; Tehranchi, 2006). These inﬂammatory
cytokines can also interfere with endogenous erythropoietin
(eEPO) production (Jelkmann et al, 1994) which may con-
tribute further to the anaemia observed in MDS patients.
Though red blood cell (RBC) transfusions are often used to
treat anaemia in patients with MDS disorders, transfusions
can be complicated by infection, difﬁcult cross match and
subsequent iron overload (Gupta et al, 1999; Gardin &
Fenaux, 2004; Balducci, 2006). As an alternative to transfu-
sions, studies have explored the efﬁcacy of erythropoiesis-
stimulating agents (ESAs) [alone and in combination with
granulocyte colony-stimulating factor (G-CSF)] to correct
MDS-induced anaemia by overcoming the inhibitory effects
of pro-apoptotic cytokines, promoting survival of erythroid
progenitors and enhancing erythropoiesis (Hellstrom-Lind-
berg et al, 1998, 2003; Hellstrom-Lindberg, 2005; Musto et al,
2005; Spiriti et al, 2005; Stasi et al, 2005; Balleari et al, 2006;
Mannone et al, 2006). A review of published studies of low-
risk MDS patients found a statistically signiﬁcant beneﬁt of
growth factor therapy (including ESAs with or without colony
stimulating factors) to both overall survival and progression-
free survival compared with non-growth factor therapies
(including differentiating agents, cytotoxic agents and immu-
nomodulators). This improvement was observed at 6, 12, 18
and 24 months of follow-up and was independent of FAB
subtype, baseline transfusion need, IPSS score, previous
treatment and time since diagnosis (Golshayan et al, 2007).
Some studies have also identiﬁed baseline classiﬁcations in
low-risk MDS patients that predicted a favourable haemato-
logical response to ESA treatment. These prognostic factors
includedeEPOconcentrations£100 mU/ml,two or fewer RBC
transfusions in the previous month and no excess blasts and/
or hypoplastic bone marrow (Rose et al, 1995; Hellstrom-
Lindberg et al, 2003; Musto et al, 2005). In patients with low
transfusion needs and low eEPO concentrations, a decision
model predicted a good chance of favourable response to ESA
treatment with or without G-CSF, and improved overall
survival and quality-adjusted life years (Sekeres et al, 2007).
Darbepoetin alfa is a novel ESA that can be administered at
extended dosing intervals, such as once every 3 weeks (Q3W)
(Kotasek et al, 2003; Canon et al, 2006). This ESA is approved
in the United States and Europe for the treatment of anaemia
in patients with chronic renal failure and for the treatment of
chemotherapy-induced anaemia (CIA) in cancer patients
(Vansteenkiste et al, 2002; Hedenus et al, 2003; Schwartzberg
et al, 2004; Herrington et al, 2005; Robinson & Easthope,
2005; Canon et al, 2006; Glaspy et al, 2006).
This single-arm phase 2 study evaluated the biological
activity and efﬁcacy of darbepoetin alfa in patients with low- or
intermediate-1-risk MDS. The primary end-point was the
percentage of patients achieving either a major or minor
erythroid response (using the International Working Group
(IWG) criteria) (Cheson et al, 2000) following the initial
13 weeks of darbepoetin alfa therapy. Prospectively deﬁned
secondary end-points evaluated the efﬁcacy of darbepoetin alfa
at 27/28 weeks and 53/55 weeks on the percentage of patients
achieving an erythroid response, the change in haemoglobin
concentration from baseline, the incidence of transfusions, the
change in patient-reported fatigue, and incidence of adverse
events.
Patients and methods
Study population
The original protocol approved on 1 March 2004 speciﬁed a
sample size of 120 patients who had not been previously
treated with an ESA. A protocol amendment was approved
on 18 May 2005 to allow patients who had previously
received an ESA to be enroled (prior ESA therapy had to
be stopped for 7 to 30 d before study enrolment). This
amendment also increased the total sample size to 200
patients. This study was designed as an estimation study to
determine major and minor response rates when darbepoetin
alfa was administered to patients with low-risk MDS with
and without prior ESA treatment to assist in planning future
MDS studies.
Written approval was received from the Institutional Review
Board at each study centre. Before study procedures (including
screening) were initiated, informed consent was obtained from
patients. All screening tests were performed within a maximum
of 7 d before enrolment, with eligible patients being enroled
within 7 d after completion of screening. An interactive voice-
response system was called to obtain a unique identiﬁcation
number for each patient. Patients who terminated prematurely
from the study were not replaced.
Patients ‡18 years were eligible for this study if they had a
haemoglobin concentration £110 g/l, adequate iron stores,
Eastern Cooperative Oncology Group status score of 0 to 2,
adequate renal and liver function and low-risk MDS (low- or
intermediate-1-risk as deﬁned by the IPSS) with a FAB
classiﬁcation of RA, RA with ringed sideroblasts (RARS) or
RA with excess blasts (RAEB) (with blasts £10%). FAB and
IPSS classiﬁcations were determined by complete blood cell
counts and bone marrow biopsies obtained within 8 weeks
before enrolment for ESA-naı ¨ve patients or 8 weeks before
initiation of ESA therapy for currently treated patients.
Patients were excluded from this study if they had a previous
bone marrow or stem cell transplant, history of transfusion-
dependent thrombocytopenia, chronic myelomonocytic leu-
kaemia, history of pure red cell aplasia, class II or IV cardiac
disease, uncontrolled hypertension, clinically signiﬁcant sys-
temic infection or chronic inﬂammatory disease, anaemia
related to nutritional deﬁciencies or other causes (including
haemolysis, bleeding, sickle-cell anaemia and renal disease),
history of malignancies other than MDS and previous or
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for ESAs (which had to be discontinued at least 7 d and not
more than 30 d before enrolment) or G-CSF, which could be
used for neutropenic fever or infection during the 30 d before
study enrolment. Patients were also excluded if they received
investigational agents not approved for any indication during
the 30 d before enrolment, received ongoing corticosteroid
therapy(otherthanaspremedicationfortransfusions),received
methotrexate or MDS-targeted therapy (including chemother-
apy, antibody-based cancer treatments, hormonal therapies,
interferons and interleukins) within 30 d before screening,
received radiotherapy in the year before screening or planned to
receive chemotherapy or radiotherapy within 28 weeks after
enrolment. Additional reasons for patient exclusion included a
positive human immunodeﬁciency virus test, positive antibody
response to an ESA, known failure of ESAs to treat anaemia and
known hypersensitivity to darbepoetin alfa or any of its
excipients. Patients were also excluded if they were pregnant,
breast-feeding or not using adequate contraception.
Study design
This was a phase 2, stratiﬁed, single-arm, open-label, multi-
centre study of darbepoetin alfa for treating anaemic patients
with MDS.
Study day 1 (no more than 4 d after enrolment) was the day
on which the ﬁrst dose of darbepoetin alfa was administered
(Fig 1). This study was prospectively divided into speciﬁc
time-points during treatment, which were related to the
primary and secondary end-points of the study. These time-
points included day 1 through to the end of week 13 (test
period) and day 1 through to weeks 28 or 27 (treatment
period, which varied depending on whether a patient was
receiving study drug Q3W or Q2W. Continued treatment with
darbepoetin alfa until week 52 (extended-treatment period)
was also included in the study to allow for additional safety
and biological assessments of the chronic administration of
darbepoetin alfa in this setting (Fig 1).
Darbepoetin alfa treatment was initiated at a dose of 500 lg
Q3W. All doses of darbepoetin alfa were administered
subcutaneously. Darbepoetin alfa was escalated to 500 lg
Q2W after 6 weeks (at week 7) of treatment for patients who
did not achieve either ‡10 g/l haemoglobin increase over
baseline levels or maintain haemoglobin levels in the range of
110–120 g/l. Subsequent doses were administered at the
frequency received as of week 7, regardless of subsequent dose
reductions. If haemoglobin concentrations increased to
between 120 and 130 g/l, darbepoetin alfa was reduced to a
dose of 300 lg at the same frequency as previously adminis-
tered. For patients receiving 500 lg darbepoetin alfa and who
had an increase >10 g/l in haemoglobin concentration in any
2-week period, the dose of study drug was reduced to 300 lg
using the most recent dosing frequency. For patients who
exceeded the haemoglobin threshold of ‡130 g/l, darbepoetin
alfa was withheld until haemoglobin levels decreased to
£120 g/l, wherein it was re-instated at 300 lg. For patients
who did not maintain a haemoglobin concentration >110 g/l
at reduced 300-lg darbepoetin alfa, doses (determined after 4
to 6 weeks at this dose) were escalated to 500 lg. Treat-
ment was permanently discontinued for any patient who
experienced a grade ‡3, non-haematological toxicity related
to darbepoetin alfa treatment.
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Week 13  Week 27/28  Week 52  Study Day 1 
Test period 
Extended-treatment period 
Treatment period 
Darbepoetin alfa 
500 µg Q3W 
Dose escalation will be considered after 6 weeks. 
Dose must be withheld if haemoglobin threshold  
is exceeded. 
Fig 1. Study schema. Darbepoetin alfa was administered at 500 lg every 3 weeks (Q3W). After 6 weeks (at week 7), the dosing frequency could be
escalated to every 2 weeks (Q2W). Treatment was withheld when a patient’s haemoglobin reached ‡130 g/l. Darbepoetin alfa treatment was not to
exceed 52 weeks, and end of study was planned for 3 weeks (at week 55 for Q3W dosing) or 2 weeks (at week 53 for Q2W dosing) after the last dose
of darbepoetin alfa was administered. Study day 1 (the ﬁrst day of darbepoetin alfa administration) to week 13 was designated as ‘test period’, study
day 1 to week 27/28 was designated as ‘treatment period’ and study day 1 to week 52 was designated as ‘extended-treatment period’.
Darbepoetin alfa for Treating MDS-induced Anaemia
ª 2008 The Authors
Journal Compilation ª 2008 Blackwell Publishing Ltd, British Journal of Haematology, 142, 379–393 381The end of study was planned for 2 or 3 weeks after the last
dose of darbepoetin alfa was administered (i.e. week 55 for
patients receiving study drug Q3W throughout the study and
week 53 for patients who switched to Q2W dosing at the
beginning of week 7).
Study drug and concomitant medications
Darbepoetin alfa (Aranesp
 ) was supplied by Amgen Inc.
(Thousand Oaks, CA, USA) as a clear, sterile protein solution
of 500 lg darbepoetin alfa per ml of polysorbate-containing
solution. Throughout the study, patients could be treated with
any concomitant medications or treatments necessary to
provide adequate supportive care except for those treatments
listed in the exclusion criteria (see ‘Study population’). Iron
supplementation was administered (to support erythropoiesis)
according to the policy of each institution.
Study end-points and assessments
The primary efﬁcacy end-point was the percentage of patients
who achieved either a major or minor erythroid response
during the initial 13 weeks (test period) of darbepoetin alfa
therapy. A major erythroid response was deﬁned as either a
‡20 g/l increase in haemoglobin concentration from baseline
(in the absence of a RBC transfusion within the preceding
28 d) or transfusion independence for patients who were
transfusion-dependent at screening (transfusion dependence
was deﬁned as at least three RBC transfusions in the 3 months
before screening). A minor erythroid response was deﬁned as
either an increase in haemoglobin concentration of ‡10 to
<20 g/l from baseline (in the absence of a RBC transfusion
within the preceding 28 d) or a 50% decrease in transfusion
requirements for patients who were transfusion-dependent at
screening. An alternative deﬁnition of erythroid response
based on the updated IWG deﬁnition (Cheson et al, 2006) was
used as a sensitivity analysis for responses during the extended
treatment period by baseline eEPO categories. This was deﬁned
as an initial increase in haemoglobin of ‡15 g/l from baseline
(in the absence of an RBC transfusion within the preceding
28 d) and an average increase in haemoglobin of ‡15 g/l from
baseline that was sustained for 8 weeks following the initial
rise. This deﬁnition made no distinction between major and
minor responses.
Prospectively deﬁned secondary end-points analysed during
the extended treatment period of darbepoetin alfa therapy
included the percentage of patients who achieved a major or
minor erythroid response, incidence of haemoglobin response
(haemoglobin concentration increase of ‡20 g/l from baseline
in the absence of RBC transfusions within the preceding
28 d), the mean change in haemoglobin levels from baseline
to week 53/55, the incidence of RBC transfusions and the
mean change in the patient-reported Functional Assessment
of Cancer Therapy-Fatigue (FACT-F) score from baseline to
week 53/55. Additional end-points analysed during the
extended treatment period included the incidence of achiev-
ing the targeted haemoglobin range of 110 to 130 g/l, the
mean haemoglobin concentration maintained after achieving
the haemoglobin target and the percentage of patients who
maintained haemoglobin concentrations within the target
range of 110–130 g/l. This haemoglobin target range was
based on evidence-based guidelines to minimize transfusion
requirements and to maximize quality of life (QOL) in cancer
patients with anaemia (Rizzo et al, 2002; Bokemeyer et al,
2004; Rodgers et al, 2005). Additional QOL measures
included the EQ-5D (Brooks et al, 2003) and three additional
patient-related outcome questions concerning energy, activity
and overall health. Safety end-points included incidence of
adverse events, the percentage of patients who exceeded the
haemoglobin threshold of ‡130 g/l, and the percentage of
patients who withdrew from the study because of disease
progression.
Complete blood count tests were performed weekly by a
central laboratory from weeks 1 to 13 and then Q3W from
weeks 13 to 28 (or Q2W from weeks 13 to 27 if the dose
frequency was escalated at week 7). Haemoglobin concentra-
tions were also measured at each dosing visit by a local
laboratory to determine if any dose adjustments were neces-
sary. A central laboratory was used to determine the presence
of antibodies to darbepoetin alfa at baseline, at week 27/28 and
at the end of study.
Statistical analysis
This ﬁnal analysis included all data up to week 53/55. Analyses
were stratiﬁed by the patient’s previous ESA therapy status
(ESA-naı ¨ve vs. prior ESA-treated), as speciﬁed in the study
protocol. sas (version 9, Cary, NC, USA) was used for all data
analyses. Categorical variables were summarized using fre-
quencies and percentages and continuous variables were
summarized using means, standard deviations and 95%
conﬁdence limits (CLs).
The primary and the safety analysis set consisted of all
enroled patients who received at least one dose of darbepoetin
alfa. The patient-reported outcome (PRO) analysis set con-
sisted of all enroled patients who received at least one dose of
darbepoetin alfa and completed both the baseline and at least
one subsequent FACT-F questionnaire.
Missing haemoglobin data, either because of a missed visit
or collected within 28 d after a RBC transfusion was imputed
in the last-value-carried-forward (LVCF) approach. In the
available data approach, missing haemoglobin values were not
imputed. In the summaries of PRO end-points, the available
data approach was used, and the data were not adjusted for
RBC transfusions.
The crude proportions of patients who had a major
erythroid response or a minor erythroid response were
summarized, and 95% CLs were constructed for the percent-
ages of patients in each category by using the normal
approximations. The percentages of patients who had a
J. Gabrilove et al
ª 2008 The Authors
382 Journal Compilation ª 2008 Blackwell Publishing Ltd, British Journal of Haematology, 142, 379–393haemoglobin response, achieved the target haemoglobin range,
or received at least one RBC transfusion were estimated using
the Kaplan–Meier (KM) method (95% CLs were based on the
normal approximation with the variance estimated using
Greenwood’s formula). Estimates of the median times to event
(with 95% CLs) were calculated and KM plots of the time to
haemoglobin response and time to target haemoglobin were
generated.
All adverse events were summarized by system organ class
and preferred term according to the Medical Dictionary for
Regulatory Activities (MedDRA version 9).
Results
Study population
This study began accruing patients on 14 May 2004 and
completed enrolment on 6 July 2005 with 80 centres enroling a
total of 209 patients. As 3 patients never received darbepoetin
alfa, analyses were conducted on a primary analysis set of 206
patients. Of the 206 patients, 18% had signiﬁcant protocol
deviations (14% failed to meet inclusion/exclusion criteria and
5% received other ESAs during this study).
Of these patients, 144 patients (70%) had never been treated
with an ESA before enrolment (ESA-naı ¨ve) and 62 patients
(30%) had been treated with an ESA before enrolment (prior
ESA-treated) (Table I). Most patients in the ESA-naı ¨ve and
prior ESA-treated strata were Caucasian and had a median age
of about 76 years. The prior ESA-treated patients began their
ESA treatment a mean (SD) of 609 (638) d prior to study
enrolment (median, 398 d). Seventeen (27%) of these patients
received darbepoetin alfa as their most recent ESA therapy,
with a mean (SD) dose of 232 (53) lg. Most (59%) of those
patients who had prior darbepoetin alfa treatment were
receiving Q2W dosing at their last dose. Forty-ﬁve (73%) of
the prior ESA-treated patients received Epoetin alfa as their
most recent ESA therapy, with a mean (SD) dose of 52 326
(18 528) U. Sixty-nine per cent of prior Epoetin alfa-treated
patients received weekly dosing at the last dose prior to study
entry.
Approximately two-thirds of all patients had baseline eEPO
concentrations of <100 mU/ml. Both ESA-naı ¨ve and prior
ESA-treated patients had a similar distribution of baseline
eEPO levels. The ESA-naı ¨ve patients had a mean (SD)
haemoglobin concentration of 97 (10) g/l and the prior ESA-
treated patients had a mean (SD) haemoglobin concentration
of 100 (11) g/l prior to initiation of darbepoetin alfa. Sixty-one
per cent of prior ESA-treated patients had an FAB classiﬁcation
of RA and 71% had an IPSS classiﬁcation of low-risk MDS. In
the ESA-naı ¨ve group, 56% had an FAB classiﬁcation of RA and
65% had an IPSS classiﬁcation of low-risk MDS. At screening,
2 (1%) of ESA-naı ¨ve patients and 7 (11%) of prior ESA-treated
patients were considered to be transfusion-dependent per
protocol (had received at least three RBC transfusions in the
3 months before screening).
The average mean (SD) weekly dose of darbepoetin alfa
administered during the entire study was 151 lg/week
(SD = 62) to ESA-naı ¨ve patients and 174 (58) lg/week to
prior ESA-treated patients. ESA-naı ¨ve patients were dosed for
a mean (SD = 16) of 41 weeks and prior ESA-treated patients
for 33 (20) weeks. The mean (SD) total number of doses
received was 14 (7) doses in the ESA-naı ¨ve group and 13 (8)
doses in the prior ESA-treated group. The percentage of
patients who had a dose withheld for reaching the haemoglo-
bin concentration threshold (‡130 g/l) was 34% in the ESA-
naı ¨ve group and 26% in the prior ESA-treated group. A total of
90 patients (44%) required a dose increase per protocol
speciﬁcations from Q3W to Q2W; 39% of ESA-naı ¨ve patients
and 55% of prior ESA-treated patients had this increase in
dose frequency.
Erythroid response at week 13
The primary efﬁcacy end-point in this study was the percent-
age of patients who achieved an erythroid response (either
major or minor response) during the ﬁrst 13 weeks of
darbepoetin alfa therapy. In the ESA-naı ¨ve patients, the crude
percentage (95% CL) that achieved a major erythroid response
was 49% (40, 57), with a minor erythroid response rate of 22%
(15, 29) (Fig 2A). In the prior ESA-treated patients, the crude
percentage (95% CL) that achieved a major erythroid response
was 26% (15, 37) and the crude percentage (95% CL) with a
minor erythroid response was 18% (8, 27). A haemoglobin
concentration increase of ‡20 g/l from baseline (which is also
the deﬁnition of a haemoglobin response) was observed in all
patients with a major erythroid response.
Response outside the test period
Seventy-seven patients did not have a major or minor
erythroid response in the 13-week test period (42 ESA-naı ¨ve
and 35 prior ESA-treated). Among these 77 patients, 4 patients
from each stratum (10% of ESA-naı ¨ve and 11% of prior ESA-
treated) subsequently had an initial erythroid response during
weeks 13 to 27/28 of the treatment period. No patients had an
initial erythroid response during weeks 27/28 to 53/55 of the
extended treatment period.
Erythroid and haemoglobin responses at week 53/55
The incidence of erythroid responses after 53/55 weeks of
treatment was also evaluated. In the ESA-naı ¨ve patients, the
crude percentage (95% CL) that achieved a major erythroid
response was 59% (51, 67), with a minor erythroid response
rate of 15% (9, 20) (Fig 2B). In the prior ESA-treated patients,
the crude percentage (95% CL) that achieved a major
erythroid response was 34% (22, 46) and the crude percentage
(95% CL) with a minor erythroid response was 16% (7, 25).
Patients achieving a 20 g/l rise in haemoglobin concentration
accounted for all major erythroid responses. Similar to
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percentage of patients who had a major response in the 53/
55-week treatment period was almost twice as high in the ESA-
naı ¨ve group as in the prior ESA-treated group. Among 119
patients who had a dose increase for any reason, 50 (42%)
achieved a major erythroid response and an additional 20
(17%) achieved a minor erythroid response.
A separate analysis looked at the percentage of patients
achieving a haemoglobin response (haemoglobin increase of
‡20 g/l from baseline in the absence of RBC transfusions
within the preceding 28 d) after 53/55 weeks of darbepoetin
alfa therapy. Thirty-one patients were not eligible for the
haemoglobin response analysis as they had received RBC
transfusions within 28 d of the baseline haemoglobin assess-
ment, and thus had baseline haemoglobin values that were
affected by recent transfusion. The KM percentage (95% CL)
of eligible patients who achieved a haemoglobin response was
68% (60, 75). In ESA-naı ¨ve patients (n = 126), the KM
Table I. Demographics, baseline characteristics
and disease state of patients. ESA-naı ¨ve Prior ESA-treated
n = 144 n =6 2
Sex, n (%)
Men 72 (50) 31 (50)
Race, n (%)
Caucasian 124 (86) 51 (82)
Other 20 (14) 11 (18)
Age, years
Mean (SD) 75Æ0 (10Æ0) 75Æ7( 9 Æ3)
Median (Min, Max) 76Æ0 (51, 93) 76Æ5 (55, 94)
Baseline eEPO category, n (%)
Less than 100 mU/ml 97 (67) 40 (65)
100 to less than 500 mU/ml 30 (21) 13 (21)
Greater than or equal to 500 mU/ml 14 (10) 7 (11)
Missing 3 (2) 2 (3)
FAB classiﬁcation, n (%)
RA 81 (56) 38 (61)
RARS 53 (37) 20 (32)
RAEB 10 (7) 3 (5)
Missing 0 (0) 1 (2)
IPSS classiﬁcation, n (%)
Low 94 (65) 44 (71)
Intermediate-1 44 (31) 14 (23)
Missing 6 (4) 4 (6)
ECOG status, n (%)
0 to 1 130 (90) 55 (89)
2 10 (7) 3 (5)
Missing 4 (3) 4 (6)
Mean (SD) baseline haemoglobin, g/l 97 (10) (n = 126) 100 (11) (n = 49)
Absolute neutrophil count
<1Æ5 · 10
9/l, n (%)
22 (15) 8 (13)
Platelets <100 · 10
9/l, n (%) 23 (16) 11 (18)
Cytogenetics, n (%)
Good 115 (80) 48 (77)
Intermediate 14 (10) 6 (10)
Poor 6 (4) 3 (5)
Unknown or not done 9 (6) 5 (8)
Transfusion-dependent, n (%)* 2 (1) 7 (11)
Mean (95% CI) baseline FACT-F score 30Æ1 (27Æ7, 32Æ6) (n = 115) 31Æ1 (27Æ6, 34Æ7) (n = 42)
ESA, erythropoiesis-stimulating agent; Min, minimum; Max, maximum; eEPO, endogenous
erythropoietin; FAB, French–American–British; RA, refractory anaemia; RARS, refractory
anaemia with ringed sideroblasts; RAEB, refractory anaemia with excess blasts; IPSS, Interna-
tional Prognostic Scoring System; ECOG, Eastern Cooperative Oncology Group; FACT-F,
Functional Assessment of Cancer Therapy-Fatigue.
*Patients who received at least three RBC transfusions in 3 months before screening were con-
sidered transfusion-dependent.
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73% (64, 81) and in prior ESA-treated patients (n = 49) the
percentage of responders was 53% (37, 70). Figure 3A shows
the KM curve for the time to haemoglobin response in both
ESA-naı ¨ve and prior ESA-treated patients during the 28-week
treatment period. As the haemoglobin response accounted for
all patients with a major erythroid response, this ﬁgure also
demonstrates the time to major erythroid response during the
treatment period. The KM median (95% CL) time to
haemoglobin response over the extended treatment period
was 11 weeks (9, 15) in ESA-naı ¨ve patients and 31 weeks (13,
NE) in prior ESA-treated patients (the upper 95% CL in prior
ESA-treated patients could not be estimated).
The KM (95% CL) percentages of patients who attained the
target haemoglobin range of 110 to 130 g/l and then
maintained haemoglobin concentrations within the target
range during the 53/55-week treatment period were also
examined. Eighty-two per cent (70, 94) of ESA-naı ¨ve patients
and 55% (40, 70) of prior ESA-treated patients achieved a
target haemoglobin concentration of 110 g/l (Table II). Fig 3B
shows the time to achieve the target haemoglobin range in
both ESA-naı ¨ve and prior ESA-treated patient populations
over the 28-week treatment period. Most ESA-naı ¨ve and prior
ESA-treated patients who attained the target haemoglobin
concentration were then able to maintain haemoglobin
concentrations within the haemoglobin target range for the
remainder of the study (Table II). After achieving the target
haemoglobin concentration, no ESA-naı ¨ve patients and only
two prior ESA-treated patients had their mean haemoglobin
concentration drop to <100 g/l.
The mean baseline haemoglobin concentrations for ESA-
naı ¨ve and prior ESA-treated patients are presented in Table I.
Using the LVCF approach to impute missing values, the mean
(95% CL) change in haemoglobin concentration from baseline
to week 53/55 was 11 g/l (8, 13) in ESA-naı ¨ve patients and 3g/l
()2,8)inpriorESA-treatedpatients (Fig 4).Usingthe available
data approach, the mean (95% CL) change in haemoglobin to
week 53/55 was 14 g/l (11, 18) for ESA-naı ¨ve patients (n = 68)
and 16 g/l (9, 22) for prior ESA-treated patients (n = 9).
Factors associated with erythroid response
IPSS score. For patients classiﬁed as low risk according to the
IPSS, the crude percentage (95% CL) that experienced major
erythroid responses during the 13-week test period was 55%
(45, 65) for ESA-naı ¨ve patients and 32% (18, 46) for prior
ESA-treated patients. Patients classiﬁed in the Intermediate-1
IPSS risk class had lower rates of response [32% (18, 46) for
ESA-naı ¨ve and 14% (0, 33) for prior ESA-treated] (Fig 5).
Baseline serum eEPO. Patients with lower serum eEPO
measured at baseline appeared to have a higher rate of
haematological response. Using the updated IWG deﬁnition
for erythroid response that does not distinguish between major
and minor responses (Cheson et al, 2006), ESA-naı ¨ve patients
at week 53/55 had responses that ranged from 60% for those
with baseline eEPO levels <100 mU/ml to 14% in those with
baseline eEPO levels ‡500 mU/ml. In prior ESA-treated
patients, erythroid responses were approximately 30% for
both these baseline eEPO categories (Table III).
Transfusions
During weeks 1 to 13 of the study, the KM percentage (95%
CL) of patients with transfusions was 17% (11, 23) in the ESA-
naı ¨ve group and 35% (22, 47) in the prior ESA-treated group.
During weeks 1 to 28, the KM percentage (95% CL) of patients
with transfusions was 18% (12, 25) in the ESA-naı ¨ve group
and 37% (24, 50) in the prior ESA-treated group. Over the
course of the study, the KM percentage (95% CL) of patients
with RBC transfusions was 28% (20, 36) in the ESA-naı ¨ve
group and 42% (29, 56) in the prior ESA-treated group.
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Fig 2. Patients who achieved an erythroid response by 13 and 53/
55 weeks. A major erythroid response was deﬁned as: i) an increase in
Hb concentration of ‡20 g/l from baseline or ii) transfusion-inde-
pendent for patients who were transfusion-dependent at screening. A
minor erythroid response was deﬁned as: i) an increase in Hb con-
centration of ‡10 and <20 g/l from baseline or ii) ‡50% decrease in
transfusion requirements for patients who were transfusion-dependent
at screening. (A) Percentage of patients achieving an erythroid
response after 13 weeks of darbepoetin alfa therapy (the primary end-
point). (B) The percentage of patients with an erythroid response after
53/55 weeks of darbepoetin alfa therapy. Error bars indicate the upper
95% CL. ESA, erythropoiesis-stimulating agent; CL, conﬁdence limit.
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study entry, 1 ESA-treated patient achieved transfusion
independence for a period during the study. Based on a
comparison of the weekly transfusion rate before screening and
the transfusion rate between 28/29 and 53/55 weeks of
treatment, 1 patient from each group achieved a ‡50%
decrease in transfusions; the remainder of those who were
transfusion-dependent at screening achieved a <50% decrease
in transfusions (1 patient in the ESA-naı ¨ve group and 6
patients in the ESA-treated group).
Change in QOL scores
The baseline FACT-F scores for the ESA-naı ¨ve and prior ESA-
treated patients are presented in Table I. The mean (95% CL)
change in FACT-F score from baseline to week 13 was 5Æ6
(3Æ5, 7Æ7) points in the ESA-naı ¨ve patients (n = 104) and 2Æ4
()0Æ9, 5Æ8) points in the prior ESA-treated patients (n = 36)
(Fig 6). The mean (95% CL) change in FACT-F score from
baseline to week 53/55 was 6Æ2( 4 Æ0, 8Æ4) points in the ESA-
naı ¨ve patients (n = 70) and 6Æ2( 1 Æ7, 10Æ7) points in the prior
ESA-treated patients (n = 17). Increases in FACT-F scores
were associated with improvements in haemoglobin levels
from baseline (Fig 6). An increase of ‡3 points in the FACT-F
score has previously been reported to be clinically signiﬁcant
(Cella et al, 2002). A separate ad hoc analysis of FACT-F by
FAB classiﬁcation did not reveal meaningful information
because of the unequal numbers of patients in each class. The
EQ-5D and additional patient questionnaire items collected
from 75% of enroled patients showed no trends over time.
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Fig 3. Kaplan–Meier plots of the time to haemoglobin response and of the time to target haemoglobin over the 28-week treatment period. (A) The
time to haemoglobin response for erythropoiesis-stimulating agent (ESA)-naı ¨ve patients and prior ESA-treated patients. (B) The time to target
haemoglobin for ESA-naı ¨ve patients and prior ESA-treated patients. n below each graph represents the number of patients at risk for an event
(patients were censored after an end-point was achieved).
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Of the 206 patients, 92% reported an adverse event (both
treatment-unrelated and related) during the 53/55-week treat-
ment period [93% of ESA-naı ¨ve patients (n = 144) and 89%
of prior ESA-treated patients (n = 62)]. The most common
adverse events reported were fatigue (37%), peripheral oedema
(18%), dyspnoea (17%) and dizziness (16%). Events occurring
in a notably greater proportion of erythropoietin-treated
patients than erythropoietin-naı ¨ve patients were fatigue (47%
vs. 33%), anaemia (16% vs. 7%) and upper respiratory tract
infection (15% vs. 4%). Events that occurred in a notably
Table II. The percentage of patients who
achieved the target haemoglobin concentration
(110 g/l) and the mean haemoglobin concen-
tration once target was achieved.
ESA-naı ¨ve Prior ESA-treated
n = 144 n =6 2
Patients eligible for target Hb analysis, n* 129 57
KM (95% CL) percentage who reached target Hb  82% (70, 94) 55% (40, 70)
KM (95% CL) median time to achieve the target
Hb, weeks
7 (5, 9) 24 (9, NE)
Patients eligible for mean Hb analysis after target
achieved, n 
105 31
Mean (SD) Hb concentration of maintenance, g/l 116 (8) 117 (8)
Median (Min, Max) Hb concentration of
maintenance, g/l
117 (99, 133) 118 (101, 136)
Mean Hb category after achieving target, n (%)
Less than 110 g/l 25 (24) 8 (26)
110–130 g/l 75 (71) 22 (71)
Greater than 130 g/l 5 (5) 1 (3)
ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; KM, Kaplan–Meier; CL, conﬁdence
limits; Min, minimum; Max, maximum; NE, not estimable.
*Patients who had haemoglobin data either at baseline or after baseline were considered eligible
except for those patients with baseline haemoglobin ‡110 g/l. Patients who had no haemoglobin
data after baseline were counted as not having achieved the target level.
 Patients had to reach the target haemoglobin level (110 g/l) in the absence of a red blood cell
transfusion within the preceding 28 d.
 Patients who had baseline haemoglobin ‡110 g/l or who achieved the target haemoglobin
concentration of 110 g/l were included.
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Fig 4. Change in haemoglobin from baseline to week 53/55. Data are presented from an analysis using the last-value-carried-forward (LVCF)
approach and from an analysis using available data. The mean change in haemoglobin is shown by baseline haemoglobin category. Error bars indicate
the upper and lower 95% CL. ESA, erythropoiesis-stimulating agent; CL, conﬁdence limit.
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erythropoietin-treated patients were dizziness (19% vs. 10%)
and pain in extremity (13% vs. 5%). Twenty-eight per cent of
ESA-naı ¨ve patients and 34% of prior ESA-treated patients
experienced serious adverse events with the most common
serious adverse event being infection (e.g., pneumonia or
sepsis).
The incidence of treatment-related adverse events was low
over the 53/55-week study period. Two patients (in the ESA-
naı ¨ve group) experienced serious treatment-related adverse
events. One patient experienced a moderate transient ischae-
mic attack at study week 37 and discontinued study partic-
ipation in response to the event which resolved on the date of
onset. The patient’s haemoglobin level was determined to be
93 g/l at the time of the event. Another patient experienced
severe hypertension at study week 10. After temporary
discontinuation of darbepoetin alfa, the hypertension resolved
10 d after onset.
Thromboembolic events (including deep vein thrombosis
or other thrombosis) were reported in 4 patients (2%). These
included aortic stenosis requiring bypass surgery, retinal
artery occlusion and thrombosis categorized as a mild blood
clot on the inner forearm. One patient experienced coagulo-
pathy with coumadin listed as the probable causative agent.
All four thromboembolic events resolved and none were
judged by the investigator to be related to study medication.
An additional 24 patients experienced events that may have
been related to embolism or thrombosis. Among patients
who had a rapid rise in haemoglobin level (deﬁned as >15 g/l
in 21 d or >20 g/l in 28 d, adjusting for RBC transfusions),
12 patients (10%) experienced thromboembolic or related
events compared with 16 patients (18%) without a rapid rise
in haemoglobin. Of those patients who exceeded the
haemoglobin threshold of 130 g/l, 6 patients (10%) experi-
enced thromboembolic or related events compared with 22
patients (15%) who did not exceed the haemoglobin
threshold. All but two of these events resolved, and only
the aforementioned transient ischaemic attack was considered
treatment-related. These additional cardiovascular events are
included with other adverse events of interest as summarized
in Table IV.
During the study, 10 patients (5%) reported disease
progression. Six of these were progression to AML or other
leukaemias as follows: 5 patients from the ESA-naı ¨ve group
including two patients with RAEB classiﬁcation (ages 64 and
76 years both discontinued study at week 29), 1 patient with
RAEB classiﬁcation (age 81 years, discontinued at week 49), 1
patient with RA classiﬁcation (age 65 years, discontinued at
week 30), 1 patient with RA classiﬁcation (age 83 years,
discontinued at week 19); and 1 patient from the prior ESA-
treated group with RAEB classiﬁcation (age 82 years, discon-
tinued at week 1). Four additional patients (3 in the ESA-naı ¨ve
group and 1 in the prior ESA-treated group) discontinued
study at weeks 17, 46, 49 and 27 because of disease progression
of unspeciﬁed type.
Eight ESA-naı ¨ve patients (6%) and 7 prior ESA-treated
patients (11%) died during the study. The causes of death
included pneumonia, sepsis, neoplasms (i.e. disease progres-
sion), cardiac disorders, respiratory arrest and unknown
causes. With the exception of pneumonia occurring in 2
patients, no events leading to death occurred in more than one
patient.
Of the 206 patients in the primary analysis set, a total of 115
patients (56%) completed the study. A higher percentage of
erythropoietin-naı ¨ve patients (63%) than erythropoietin-
treated patients (40%) completed the study. Among patients
who did not complete the study, the most common reasons
were administrative decision (12%), other (7%), consent
withdrawn (7%), adverse event (6%) and death (5%). No
patients had positive results in the darbepoetin alfa neutral-
izing antibody assay in this study.
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Fig 5. Major and minor erythroid responses during the 13-week test
period by IPSS classiﬁcation. The percentage of patients achieving an
erythroid response during the 13-week test period is shown for
patients with Low and Intermediate-1 (Int-1) IPSS classiﬁcations, and
stratiﬁed by prior ESA treatment status. IPSS, International Prognostic
Scoring System; ESA, erythropoiesis-stimulating agent; CL, conﬁdence
limit.
Table III. The percentage of patients who achieved an erythroid
response over the 53/55-week study classiﬁed by baseline eEPO.
ESA-naı ¨ve Prior ESA-treated
Patients achieving an
erythroid response, n (%)*
Baseline eEPO <100 mU/ml 58 (60) (n = 97) 12 (30) (n = 40)
Baseline eEPO ‡100 mU/ml
and <500 mU/ml
13 (43) (n = 30) 2 (15) (n = 13)
Baseline eEPO ‡500 mU/ml 2 (14) (n = 14) 2 (29) (n =7 )
ESA, erythropoiesis-stimulating agent; eEPO, endogenous erythro-
poietin.
*Erythroid response was deﬁned as an initial increase in haemoglobin
of ‡15 g/l from baseline (in the absence of an RBC transfusion within
the preceding 28 d) and an average increase in haemoglobin of ‡15 g/l
from baseline that was sustained for at least 8 weeks following the
initial rise.
J. Gabrilove et al
ª 2008 The Authors
388 Journal Compilation ª 2008 Blackwell Publishing Ltd, British Journal of Haematology, 142, 379–393Discussion
Erythropoiesis-stimulating agent therapy may be able to
correct anaemia in MDS patients by enhancing the survival
and maturation of erythroid precursors (Hofmann & Koefﬂer,
2005). Previous studies have shown that recombinant human
erythropoietin (rHuEPO) can induce a response (raise hae-
moglobin levels and reduce transfusion requirements) in about
30% of low-risk MDS patients (Rose et al, 1995; Hellstrom-
Lindberg et al, 1998; Hellstrom-Lindberg, 2005). When
administered with G-CSF, the percentage of low-risk MDS
patients who respond to rHuEPO therapy may increase to
about 40% (Casadevall et al, 2004; Catenacci & Schiller, 2005;
Balleari et al, 2006), particularly in the RARS subtype (Hell-
strom-Lindberg et al, 1998, 2003). Several evidence-based
guidelines have supported the use of ESAs for treating
anaemia in MDS patients, albeit at higher doses than
those used for patients with CIA (Alessandrino et al, 2002;
Greenberg et al, 2006).
This study suggests that darbepoetin alfa may also be an
effective therapy for treating anaemia associated with MDS.
Results indicated that darbepoetin alfa 500 lg Q3W was well
tolerated and capable of meaningfully increasing haemoglobin
levels over a 53/55-week period in low-risk MDS patients. The
study patients were able to achieve a major erythroid response,
a target haemoglobin of 110 g/l and maintain haemoglobin in
the range of 110 to 130 g/l (consistent with the range
recommended by evidence-based guidelines at the time for
ESA therapy) (Rizzo et al, 2002; Bokemeyer et al, 2004;
Rodgers et al, 2005). In addition, treatment with darbepoetin
alfa appeared to reduce fatigue. Transfusion requirements
were 28% in ESA-naı ¨ve and 42% in prior ESA-treated
populations over the 53/55-week treatment period. An effect
of darbepoetin alfa therapy on transfusion incidence over time
may have been difﬁcult to detect because overall transfusion
requirements in this study were relatively low, reﬂecting the
fact that most patients in this study were not transfusion-
dependent at screening. As the study did not include an
untreated control group, further assessment of efﬁcacy was
not possible.
It is important to identify patients for whom ESA treatment
may have a lower probability of success. Although not an
end-point of this study, based on previously suggested
predictors of haematological response (Rose et al, 1995;
Hellstrom-Lindberg et al, 2003; Musto et al, 2005), we
examined factors associated with erythroid responses. In this
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Fig 6. Change in Functional Assessment of Cancer Therapy-Fatigue (FACT-F) score from baseline. The mean change in the FACT-F score from
baseline to weeks 13 and 25 is shown by mean changes in haemoglobin levels. Error bars indicate the upper or lower 95% CL. ESA, erythropoiesis-
stimulating agent; CL, conﬁdence limit; Hb, haemoglobin.
Table IV. Adverse events of interest.
ESA-naı ¨ve
Prior
ESA-treated
n = 144 n =6 2
Patients who had adverse events of
interest, n (%)
34 (24) 21 (34)
Neoplasms benign, malignant and
unspeciﬁed, n (%)
12 (8) 9 (15)
Hypertension, n (%) 7 (5) 4 (6)
Cardiovascular and thromboembolic
events
18 (12) 10 (16)
Arrhythmias, n (%) 5 (3) 2 (3)
Cerebrovascular accident, n (%)* 6 (4) 1 (2)
Congestive heart failure, n (%) 4 (3) 2 (3)
Myocardial infarction/coronary artery
disorders, n (%)
3 (2) 3 (5)
Embolism/thrombosis, n (%) 1 (1) 3 (5)
Immune system disorders, n (%) 1 (1) 0 (0)
Seizure, n (%) 1 (1) 0 (0)
Pure red cell aplasia 0 (0) 0 (0)
ESA, erythropoiesis-stimulating agent.
*Includes ﬁve thrombotic events, one haemorrhagic event and one
event of unknown aetiology.
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(major or minor) during the study did so during the 13-week
test period. The low percentage of patients who had a ﬁrst
erythroid response during weeks 13 to 27/28 of the treatment
period and the lack of any initial erythroid responses from
week 27/28 to the end of study suggest that patients without a
change in haemoglobin by 13 weeks of treatment independent
of transfusion may not beneﬁt from continued therapy. In
patients with eEPO levels <100 mU/ml, a trend towards more
favourable response was observed in accordance with previous
reports (Rose et al, 1995; Hellstrom-Lindberg et al, 2003;
Musto et al, 2005). Patients with a low risk score in the IPSS
classiﬁcation system also appeared to respond to ESA
treatment more frequently than did those with an Interme-
diate-1 score (Fig 5). Baseline transfusion requirement is
another recognized predictor of response to therapy. How-
ever, because of the low number of patients receiving frequent
transfusions at study entry (Table I), this could not be used as
a predictive factor in this study. It is interesting to note that
patients who were ESA-naı ¨ve responded more robustly to
treatment with darbepoetin alfa than patients who had been
previously treated with an ESA. The reasons for the response
difference by prior treatment status are unclear. As the
majority of previously ESA-treated patients had been on
treatment for over a year, there were probably differences in
duration of disease between the groups. A further contribut-
ing factor may have been the lower baseline eEPO values in
the ESA-naı ¨ve group (Table III).
The safety proﬁle reported in this study was similar to that
reported in other darbepoetin alfa studies in the setting of CIA
(Vansteenkiste et al, 2002; Hedenus et al, 2003). During the
53/55-week treatment period, thromboembolic events only
occurred in 2% of MDS patients, all of which resolved. This
rate is somewhat lower than that observed in patients with CIA
treated with ESAs. Overall, hypertension was experienced by
5% of patients, but occurred in 10% of patients who exceeded
the threshold haemoglobin level of 130 g/l compared with 3%
of those who remained below the haemoglobin threshold. This
was the only adverse event that appeared potentially related to
exceeding the haemoglobin threshold of 130 g/l in this study.
This withholding level was consistent with the product
information (Amgen Inc.) for darbepoetin alfa in CIA when
this study was designed, although the current product
information states that darbepoetin alfa be temporarily
withheld if haemoglobin levels exceed 120 g/l in patients with
CIA. We observed a low rate of disease progression to AML or
other leukaemias, in accordance with other studies evaluating
the use of darbepoetin alfa (Stasi et al, 2005; Mannone et al,
2006) or erythropoietin alfa (Hellstrom-Lindberg et al, 1998)
in low-risk MDS patients. Two retrospective cohort studies
have also shown no negative impact of ESAs on AML
progression or overall survival in MDS patients (Jadersten
et al, 2005, 2006).
Other studies have also examined the efﬁcacy of darbepoe-
tin alfa for treating anaemia in MDS patients. One pilot study
and one phase 2 study have shown that darbepoetin alfa
administered 150 lg/week to low- or intermediate-risk MDS
patients can induce a major erythroid response in 35–40% of
patients without apparent safety concerns (Musto et al, 2005;
Stasi et al, 2005). In a phase 2 study that examined
darbepoetin alfa administered 300 lg/week with or without
G-CSF, 55% of low-risk MDS patients treated with darbepoe-
tin alfa alone achieved a major erythroid response; additional
responses were obtained in patients who had been unrespon-
sive to darbepoetin alfa as a single agent when G-CSF was
administered concomitantly with darbepoetin alfa (Mannone
et al, 2006). Results from a recent retrospective cohort study
suggested that darbepoetin alfa and Epoetin alfa were equally
effective in treating MDS-induced anaemia (Patton et al,
2005).
In conclusion, the ﬁndings presented here suggest that
treating low-risk MDS patients with darbepoetin alfa
provides a clinical beneﬁt for an otherwise debilitating
chronic anaemia. This study of low-risk MDS patients
treated with darbepoetin alfa for 53/55 weeks resulted in
excellent response rates with infrequent drug dosing. The
ability to administer darbepoetin alfa therapy at extended
dosing intervals, such as Q2W or Q3W, may contribute to
increased patient convenience by reducing the number of
clinic visits for anaemia treatment. This feature of darbe-
poetin alfa may be especially advantageous for patients who
require ESA therapy for treating anaemia over a long period
of time. Future studies are needed to further investigate the
efﬁcacy and safety of darbepoetin alfa in MDS patients
(both low-risk and high-risk) to identify predictors of
response to darbepoetin alfa therapy and to also evaluate the
impact of darbepoetin alfa therapy on QOL in this patient
population.
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